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Background: Dirofilaria repens is the causative agent of subcutaneous dirofilariosis of dogs, other animals and humans.
This nematode is transmitted by mosquitoes of Aedes, Anopheles and Culex genera. In dogs, the parasite may cause
subclinical infection or cutaneous signs. Recently, D. repens has emerged and spread in different geographical areas,
with an increase of cases in dogs and humans. Chemoprevention in dogs in endemic areas is the most reliable
approach for controlling this infection. This paper describes a randomized, blocked and multicentric clinical field study
investigating the efficacy of an oral, chewable formulation containing milbemycin oxime/praziquantel (Milbemax®,
Novartis Animal Health) in the chemoprevention of subcutaneous dirofilariosis in dogs.
Methods: This study was conducted in endemic areas of Italy. A total of 249 dogs, at two sites, negative for D. repens,
were allocated into two groups (i.e. Treated -T1 vs Untreated-T2) with a ratio of 1:1, and subjected to clinical visits and
blood sampling once monthly until the end of the study. All blood samples were microscopically and genetically
examined. Animals belonging to T1 group received a minimum target dose of 0.5 mg/kg bodyweight of milbemycin
oxime and 5 mg/kg of praziquantel in commercial tablets (Milbemax®) according body weight once every 4 weeks.
Animals of group T2 were not treated with Milbemax® but received, when necessary, specific parasiticide treatments.
The study duration was 336 ± 2 days for each dog.
Results: A total of 219 dogs completed the study (i.e. 111 in T1 and 108 in T2), while 30 dogs (i.e. 13 in T1, 17 in T2)
were withdrawn for a variety of reasons unrelated to administration of Milbemax®. The percentages of animals not
showing microfilariae of D. repens were 100% (111 animals) in T1 and 94.7% (108 animals out of 114) in group T2.
Milbemax® was shown to be safe in treated dogs.
Conclusions: The results of this study confirm that the monthly use of Milbemax® in dogs is effective and safe for the
prevention of subcutaneous dirofilariosis in endemic areas.
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The nematode Dirofilaria repens (Nematoda, Onchocerciidae),
the causative agent of subcutaneous dirofilariosis in dogs
and other animals, is transmitted by bites of mosquitoes
belonging to different genera, e.g. Aedes, Anopheles and
Culex [1,2]. The adult stages live in the subcutaneous tis-
sues of the definitive host and, after mating, the females
release the first stage larvae (microfilariae -mff) into the
bloodstream of the infected animal [3].
In dogs, the infection may be asymptomatic although
cutaneous signs of varying severity, such as dermatitis,
(sub)-cutaneous nodules and lesions, itching and various
allergic reactions could be caused by both adult stages
and/or circulating mff [3-6]. Importantly, this nematode
has a zoonotic potential and the human infection usually
presents with subcutaneous nodules, pruriginous urticar-
ioid patches, transient swellings and eosinophilia, although
photophobia, conjunctival irritation and nodules or cysts
in the eye or in the periocular tissues have also been
reported [7,8].
Canine subcutaneous dirofilariosis is distributed through-
out the entire European territory, with different preva-
lence rates according to the geographical region
[2,9,10]. While the occurrence of D. repens in southern
Europe is well known [2,11,12], in the last few years
the nematode has spread in previously free regions of
eastern and central regions of the Old Continent, e.g.
Austria [13,14], Czech Republic [15], Germany [16-18],
Hungary [19], Slovak Republic [20] and Ukraine [21]. Im-
portantly, the number of human cases is increasing in sev-
eral countries, e.g. Italy, Slovak Republic, Hungary and
Poland [3,7,8,22-25].
The spread of D. repens has likely been nurtured by a
variety of factors, e.g. climatic changes, increased transport
of goods across the world, reduction of movement restric-
tions of animals, movements of pets from endemic to free
regions (e.g. adoption of infected animals and travels of
companion animals with their owners), changes in the dis-
tribution of arthropods and pathogens they may transmit,
as demonstrated by the case of the Asian tiger mosquito
Aedes albopictus [1,2,26-28]. Treatment and control of
D. repens is pivotal to reduce the transmission in dogs and
to minimize the risk of infection in humans. The elimin-
ation of adult stages and circulating mff in infected dogs
(e.g. via the administration of macrolactones) may interrupt
the transmission of D. repens to the vectors [12,19,29,30].
However, the most reliable approach to control canine diro-
filarioses is the chemoprevention in healthy dogs living in
endemic areas. While several molecules are licensed to pre-
vent the canine heartworm Dirofilaria immitis [2,3,31], lit-
tle information is available regarding the prevention of
subcutaneous infections by D. repens. At this time, oral
ivermectin and injectable and spot-on moxidectin are li-
censed for the prevention of subcutaneous dirofilariosis indogs [3,30]. Oral products containing milbemycin oxime
are effective for the prevention of cardiopulmonary filariosis
in dogs [3,32,33] but the usefulness of this macrocyclic lac-
tone in the chemoprophylaxis of D. repens is practically un-
known. Thus, the present clinical field study evaluated the
efficacy and safety of a monthly administration of an oral,
chewable formulation containing milbemycin oxime in the
chemoprevention of D. repens infection in dogs living in
endemic areas.Methods
Authorizations and ethical statements
The study was carried out according to the European
and national regulatory requirements and in compliance
with the principles as on the follows:
– Directive 2001/82/EC as amended by 2004/28/EC
and 2009/9/EC;
– VICH GL9 (GCP 6.June 2000) (CVMP/VICH/595/
98 – FINAL): Guideline on good clinical practice for
the conduct of clinical trials for veterinary medicinal
products;
– EMEA/CVMP/816/00-Final: Guideline on statistical
principles for veterinary clinical trials,
– VICH GL7 “Guideline on efficacy of anthelmintics,
general requirements” (Step 7, CVMP/VICH/832/
99-corr);
– VICH GL19 “Guideline on efficacy of anthelmintics,
specific recommendations for canines” (Step 7,
CVMP/VICH/835/99-Final);
– World Association for the Advancement of
Veterinary Parasitology (W.A.A.V.P.) guidelines for
evaluating the efficacy of anthelmintics for dogs and
cats (Accepted 31 August 1993);
– The rules governing medicinal products in the
European Union, Volume VII: Guidelines for the
testing of veterinary medicinal products:
Anthelmintics for cats and dogs: Specific
requirements, (EudraLex guideline 7AE13a);
The study design and procedures were approved and au-
thorized by the Italian Ministry of Health (date and
authorization number 31.05.2012, 0010252-P). Competent
local veterinary services (Azienda Sanitaria Locale -A.S.L.)
were notified (04APR12 and 20.12.2014- 0148890, respect-
ively) and no objections were raised.
No dogs included in the trial received any parasiticide
with repellent activity, thus they were treated monthly
with a spot-on combination of metaflumizone and ami-
traz (Promeris®, Zoetis) for the control of major ecto-
parasites and received a vaccine against Leishmania
infantum (CaniLeish®, Virbac) according to manufac-
turer’s instructions.
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The trial was a blinded, randomized, blocked and clinical
field study evaluating the preventive efficacy and safety of
an oral, chewable formulation containing 0.5 mg/kg mil-
bemycin oxime and 5 mg/kg praziquantel (Milbemax®,
Novartis Animal Health) against subcutaneous dirofilario-
sis in dogs living in an endemic area of Italy, compared to
an untreated control group.
The study was carried out from April 2012 to July 2013
and in two sites of the Abruzzo region, central Italy: a
shelter located in Castelbasso municipality (Site A), and a
private practice located in Roseto degli Abruzzi municipal-
ity (Site B). In total, 233 dogs at Site A and 16 dogs at Site
B, that were both microscopically and molecularly (sec-
tions 2.2 and 2.3) negative for D. repens were enrolled.
These dogs were evaluated for inclusion/exclusion criteria
(section 2.2.1) and then definitively enrolled in the study
on Day 0.
Dogs were allocated into two groups (i.e. Treated -T1
vs Untreated-T2) with a ratio of 1:1, and subjected to
clinical observations and blood sampling once monthly
until the end of the study.
Animals belonging to T1 group received a minimum
target dose of 0.5 mg/kg bodyweight of milbemycin oxime
and 5 mg/kg of praziquantel. The product was adminis-
tered using commercial tablets in the appropriate size and
amount of tablets for the animal weight band (based on
the actual body weight) once every 4 weeks. The total dur-
ation of the study was 336 ± 2 days for each dog.
Screening: inclusion and exclusion criteria
Dogs were enrolled when fulfilling the following inclu-
sion criteria:
– weighing ≥ 1.0 kg - 75.0 kg;
– living and/or frequently walking in an area with a
prevalence of mosquitoes known to transmit D. repens;
– negative for microfilariae of D. repens and D. immitis
upon modified Knott’s test and PCR at a screening
performed one month prior to enrolment;
– treated with commercial Milbemax® no sooner than
4 weeks prior to enrolment in the study;
– clinically free of signs of infections with D. repens;
– suitable for the study when examined physically on
Day 0;
– written consent signed by the owner or by an
authorized representative.
Animals which did not fulfil the inclusion criteria or
which showed one of the following exclusion criteria
were excluded from the study:
– unstable health condition needing veterinary
treatments prior to enrolment;– clinical signs of infections with D. repens and/or
D. immitis;
– treated with a product that has efficacy on D. repens
(e.g. all macrocyclic lactones) less than 4 weeks prior
to study start;
– dogs which received a repellent treatment within the
last 14 days prior to enrolment;
– animals with any history of apparent reactions to
Milbemax® or any of its compounds.
– animals with pre-existing medical and/or
surgical conditions.
Sample collection and laboratory examinations
Samples
Blood samples were collected from each dog into EDTA
tubes (2.5 ml) at days 28 ± 2, 56 ± 2, 84 ± 2, 168 ± 2, 196 ±
2, 224 ± 2, 252 ± 2,280 ± 2, 308 ± 2 and 336 ± 2.
Samples were identified individually by unique identifi-
cation numbers and stored at +4°C until direct transport
within one day to the laboratory. According to the circa-
dian rhythm of D. repens microfilariaemia [34] the collec-
tion was performed, in the morning before 10:00 o’clock
or in the evening after 18:00 hours.
Microscopic methodologies
All blood samples were subjected to a qualitative modified
Knott’s technique as previously described in the literature
[35,36]. Microfilariae were identified on the basis of differ-
ential morphometric (i.e. length and width) and morpho-
logical (i.e. head and tail) characteristics [36,37]. For each
positive sample the level of microfilariaemia was calcu-
lated using a slightly modified protocol described in the
literature [38]. Briefly, one ml of blood was mixed with
9 ml of distilled water in a Falcon tube. The tube was thor-
oughly homogenized and an inverted McMaster Chamber
was filled with a pipette. After two minutes the chamber
was examined under a light microscope at 10X magnifica-
tion and the mff were identified and counted. The number
of mff counted in 0.30 ml of the McMaster chamber was
multiplied × 30 (i.e. sensitivity for a 1:9 dilution) in order
to obtain the number of mff in 1 ml of blood.
PCRs
The tubes containing the blood samples were left at room
temperature for at least 20 minutes to allow the sedimenta-
tion of the mff, if present. An aliquot of ~150 μl of blood
collected from the bottom of each tube was subjected to
the DNA extraction using the commercial kit NucleosSpin®
Blood (Macherey-Nagel, Duren, Germany). All DNA ex-
tracts were undertaken to semi-nested PCR protocols spe-
cific for mitochondrial gene encoding for subunit b of the
cytochrome oxidase 1 (cox1) of canine filariae as previously
described [31,39]. In the first round, the universal primer
set for spirurid nematodes COIintF (5′-TGATTGGTG
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AGTATCAATATC-3′) were used. In the second round the
specific reverse primers Dimm-cox1 R (5′-GCACTGAC
AATACCAAT-3′) for D. immitis, Drep-cox1 R (5′-TCA
AACAGAAGTACCTAAA-3′) for D. repens and Drec-
cox1 R (5′-CTGTGATGATTGGTTCT-3′) for A. recondi-
tum were used, together with the COIintF forward primer.
To confirm the identity of the species-specific PCRs, all
amplicons visible on an agarose gel were purified over
minicolumns (Ultrafree-DA, Millipore, Milan, Italy) and
sequenced using a Taq DyeDeoxyTerminator cycle se-
quencing kit in an ABI-PRISM model 377 sequencer
(Perkin Elmer, Warrington, UK). Accuracy was achieved
by two-directional sequencing, and all electrophero-
grams were manually checked and edited as necessary. Se-
quences were compared in silico with sequences of filarial
mtDNA available in the GenBank™ using the Nucleotide-
Nucleotide “Basic Local Alignment Search Tool” [40].
Once one microfilaria of D. repens had been detected by
Knott’s test or in the case of positive result at PCR, the
sample was regarded as positive.
Physical examinations
For safety evaluation, during the study period, from Day of
first treatment administration to study completion, all
dogs treated with Milbemax® and all untreated animals
were clinically observed within the scheduled study proce-
dures. Additionally, owners were requested to inform the
investigator whenever they observed any abnormalities in
their animal(s). Any abnormality observed after the first
treatment related or not to Milbemax® was recorded as an
adverse event (AE). Any adverse event, which resulted in
dead or in life-threatening or persistent or significant dis-
ability/incapacity was recorded as serious adverse event
(SAE). Any AE suspected to be a drug reaction was re-
corded as suspected adverse drug reaction (SADR).Statistical analysis and efficacy evaluation
Data from all study animals were entered directly into
an electronic data capture system (StudyBase®) purposed
for the present work. At the end of the study all verified
data were subjected to a statistical analysis.
All animals receiving at least one dose of Milbemax® and
all control dogs were included in the safety analysis. In
particular, all dogs with at least one post-baseline labora-
tory result for D. repens mff, and with a negative result for
mff until day 168 ± 2 (i.e. 6 months after the first possible
infection in 2012) formed the Intention-to-Treat (ITT)
population. Animals with a positive result for D. repens
before day 168 ± 2 were withdrawn from the study as they
turned out as having been positive for D. repens on Day 0,
and data of these animals were excluded from the
ITT population.Animals with premature discontinuation of the study
for a reason other than positive result for D. repens were
also excluded from the ITT population. The ITT popu-
lation was used for the analysis of efficacy.
The primary and secondary efficacy criteria which evalu-
ated the superiority of Milbemax® compared to the un-
treated control group were: i) percentage of animals not
showing mff of D. repens and ii) mean mff count as
assessed on the day of study completion compared between
treatment groups.
Fisher’s Exact tests and related confidence intervals were
performed with SAS® univariate procedures in order to
calculate summary statistics and confidence intervals for
means (SAS 9.2 Help and Documentation, Cary, NC: SAS
Institute Inc., Copyright 2010). All variables measured in
the study were described descriptively, and stratified by
treatment group. For continuous variables, the following
descriptive statistics were calculated: mean, standard devi-
ation, sample size, median, quartiles, minimum and max-
imum. For categorical or binary variables, absolute and
relative frequencies were analyzed. The first efficacy criter-
ion was statistically evaluated using the Fisher’s exact test
with a 95% confidence interval, while for the second effi-
cacy criterion dog groups were compared using a two-
sample t-test, if the normality assumption was satisfied for
the log-transformed data. Otherwise, the non-parametric
Mann–Whitney U test was used. Arithmetic means were
analysed with 95% confidence limits on a base of log-
transformed data and for original counts. A 5% level of
significance (two-sided, P < 0.05) was used to assess statis-
tical differences. The safety criteria percentage of adverse
events (AE) per treatment group, percentage of serious ad-
verse events (SAE) per treatment group and percentage of
suspected adverse drug reactions (SADR) per treatment
group were analysed per treatment group comparison
using Fisher’s exact test.
Results and discussion
Overall, 116 and 117 dogs were enrolled in T1 and T2 at
Site A, while 8 dogs were recruited in each treatment
group at Site B. At site A, 10 dogs continued the study
after adoption by private owners in the region of Abruzzo,
and 34 animals continued the study after a transfer from
site A to Marche region, northward from Abruzzo region.
At site B, 2 privately owned dogs moved with their
owners, one to the region Lazio and one to the region
Apulia, and continued the study (Figure 1). The study was
completed by 219 dogs (i.e. 111 in T1 and 108 in T2),
while 30 dogs (i.e. 13 in T1, 17 in T2) were withdrawn ei-
ther because they scored positive for D. repens (only for
T2 group), i.e. 6 dogs, 4 at both microscopy (Figure 2) and
PCR examinations and 2 only at the PCRs, or for other
reasons (i.e. 24 dogs). The discrepancy in the microscopic
and PCR results for T2 dogs which scored positive for
Figure 1 Map of Italy. Regions included in the study are indicated.
Di Cesare et al. Parasites & Vectors 2014, 7:347 Page 5 of 8
http://www.parasitesandvectors.com/content/7/1/347D. repens during the study could be explained by a num-
ber of circulating mff lower than the sensitivity threshold
of the Knott’s test.
None of the dogs belonging to T1 and T2 groups
showed clinical signs related to the infection, and noFigure 2 Knott’s modified method: microfilaria of
Dirofilaria repens.mixed infections with other dog filariae were recorded in
positive animals of the T2 group.
From the original population of 249 dogs, 244 were
the animals with post-baseline laboratory results for
microfilariae of D. repens and 19 of them were excluded
from the ITT population.
Based on the ITT population, the percentages of animals
testing negative for mff of D. repens (i.e. first criterion of
efficacy) were 100% (111 animals) in T1 and 94.7% (108
animals out of 114) in T2. This difference was significant
(p = 0.0293). With regard to the second criterion of effi-
cacy, mff counts were assessed for the four dogs scored
positive for the nematode at the Knott’s test, all in group
T2. The arithmetic mean mff count was 18.0.
Although adverse events were observed in 16 (10 in T1
and 6 in T2) dogs during the study (e.g. gastric torsion,
gastric and splenic torsion, bite wounds, tumours, natural
death, dermatitis, giardiosis), none were regarded as re-
lated to the study medication. The percentage of animals
with at least one adverse event and the percentage of ani-
mals with serious adverse events were comparable in both
groups, (p = 0.3151 and p = 0.7688, respectively). This
study reports the results of the first field investigation on
the efficacy and safety of an oral, chewable formulation
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Novartis Animal Health) in the chemoprevention of the
zoonotic canine infection by D. repens. The percentage of
animals negative to D. repens demonstrated the superiority
of Milbemax® in the prevention of subcutaneous dirofilar-
iosis, compared to the untreated control group (p =
0.0293), in an endemic area. In fact, all T1-dogs (i.e. dogs
which received the monthly anthelmintic formulation)
remained negative for the presence of D. repens mff
through the end of the study while 6 belonging to the un-
treated group T2 became infected during the study. This
infection rate (i.e. 5.1%) is similar to that (i.e. 5.6%) de-
scribed in a previous study carried out in the same area
[41]. Importantly, all dogs that became microfilariemic re-
ceived a rescue treatment, which showed a 100% efficacy
in treating the infection (data not shown).
Different factors have recently promoted the spreading
of D. repens and, indeed, the nematode is now emerging
in several previously free areas [1,26-28]. Chemopreven-
tion by the administration of macrocyclic lactones in
healthy dogs living in endemic areas is the most reliable
approach to control canine filarioses and to minimize its
zoonotic impact. In fact, macrocyclic lactones have sev-
eral anti-nematode applications in small companion ani-
mal medicine and, importantly, they can be used as
chemopreventatives against canine heartworm infection
for their retroactive activity in killing third- and fourth-
stage larvae. Specifically, oral (e.g. ivermectin, milbemy-
cin oxime), topical (selamectin, moxidectin) or injectable
sustained release (i.e. moxidectin) products are licensed
for heartworm prevention in dogs and/or cats. Few of
these molecules have been evaluated for their efficacy in
preventing D. repens infection. Monthly administrations
of oral ivermectin and moxidectin [42-45] and topical
selamectin [11] have been reported to be effective to pre-
vent D. repens infections in dogs. A single microsphere
sustained release injectable moxidectin treatment at the
dose of 0.17 mg/kg was effective in assuring an at least 6-
months lasting protection of dogs against D. repens [46].
Two recent trials have shown the preventive efficacy of
monthly applications of 2.5% spot on moxidectin against
D. repens in dogs, with a 100% efficacy of a single adminis-
tration in experimental infections with infective larvae
[30]. Moreover, the potential use of the same formula-
tion in the simultaneous prevention of major dog filarioses
(i.e. D. immitis, D. repens, and Acanthocheilonema recon-
ditum) has been demonstrated preliminarily [47].
The present study provides evidence for the first time
that oral milbemycin oxime is both effective and safe in
the chemoprevention of D. repens infection in dogs living
in an endemic area when administered once every 30 days.
Importantly, the frequency of periodic oral dosing with
milbemycin oxime to prevent D. repens is aimed not at
maintaining steady levels of the compound in the blood ortissues of the host, but rather to obtain a retroactive effi-
cacy on third and fourth-stage larvae in the tissue of dogs
which received bites from infected mosquitoes. Moreover,
Milbemax® at the same dosage may provide control of
major canine intestinal nematodes [48], Spirocerca lupi
[49], the zoonotic eyeworm Thelazia callipaeda [50,51],
Angiostrongylus vasorum and Crenosoma vulpis [52,53].
This broad spectrum of activity, which assures a
monthly prevention of filariae and continued control of
intestinal infections and other parasites, could make an
“all year round” worm control program desirable. In-
deed, in the USA, there is the frequent willingness of
many pet owners to administer lifelong monthly treat-
ments of macrocyclic lactones to provide reliable con-
trol against intestinal nematodes and D. immitis at the
same time [48,54]. Although the year-round approach
is not currently applied in many parts of Europe and
not recommended by The European Scientific Council
of Companion Animal Parasites (ESCCAP), this ap-
proach may considered to be advisable in particular
epidemiological settings to assure treatment, preven-
tion and/or control of major canine parasites, includ-
ing mosquito-borne nematodes. This is particularly
important if one bears in mind that D. repens is spread-
ing into geographic areas previously free of this para-
site and the number of clinical cases of D. repens in
dogs and humans is also rising in areas where canine
heartworm (D. immitis) is endemic [2,3,10,24].
Conclusions
The results of this study demonstrate that the oral,
chewable tablet containing milbemycin oxime and prazi-
quantel (Milbemax®) provides a new and effective way to
control canine subcutaneous filariosis, i.e. a zoonotic
parasitosis, which is spreading in several European coun-
tries. Specifically, the prophylactic activity of Milbemax®
in preventing D. repens is due to the macrocyclic lactone
contained in the formulation.
A regular monthly treatment with Milbemax® has the
potential to interrupt the life cycle of D. repens, with im-
portant implications under epidemiological and clinical
standpoints. In fact, minimizing the number of infected
dogs acting as reservoirs of the parasite is central to avoid
infective blood meals for the mosquitoes and to reduce
the occurrence of D. repens in their vectors, in dogs and
humans. From a practical standpoint, the prevention of
D. repens infection is important in canine clinical practice,
as adult parasites and/or circulating mff may induce differ-
ent cutaneous signs in infected dogs and pose challenging
issues for the diagnosis and treatment of these dog derma-
topathies [3-6].
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